A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e. g. , during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
Richard J. Bram - Rochester MN, US Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C07K 14/435 A61K 38/17
US Classification:
530350, 530300, 514 12
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e. g. , during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
Richard Bram - Memphis TN, US Gotz Bulow - Memphis TN, US
Assignee:
St. Jude Children's Research Hospital, Inc.
International Classification:
G01N033/567 A61K039/395
US Classification:
424/133100, 435/007210
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
Richard Bram - Rochester MN, US Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A01K067/027 C12N005/06
US Classification:
800018000, 435354000
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
Richard J. Bram - Rochester MN, US Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A61K 39/00 A61P 35/00
US Classification:
4241851
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml, Nucleic Acids Encoding The Same And Methods Of Use Thereof
Richard J. Bram - Memphis TN Gotz Von Bulow - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C07K 14705
US Classification:
530350
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e. g. , during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Dna Encoding Calcium-Signal Modulating Cyclophilin Ligand
Richard J. Bram - Memphis TN Gerald R. Crabtree - Woodside CA
Assignee:
The Board of Trustees of the Leland Stanford Junior Univ. - Stanford CA
International Classification:
C12N 508 C12N 1512
US Classification:
4352402
Abstract:
DNA and protein compositions are provided for calcium-signal modulating cyclophilin ligand which are shown to act in the calcium-dependent pathway for activation of a number of genes. The DNA composition and proteins may be used in investigating the processes associated with calcium-dependent activation of genes, as well as screening of drugs for interaction with the subject proteins for modulating cell processes, e. g. T-cell activation.
Nucleic Acids Encoding A Lymphocyte Surface Receptor That Binds Caml
Richard J. Bram - Memphis TN Gotz Von Bulow - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12N 1500 C12N 1563 C12N 500 C07H 2102 C07H 2104
US Classification:
435 691
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e. g. , during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Mayo ClinicMayo Clinic Pediatric Hematology/Oncology 200 1 St Sw Mayo 16, Rochester, MN 55905 5072842695 (phone), 5072840727 (fax)
Education:
Medical School Stanford University School of Medicine Graduated: 1987
Conditions:
Anemia Hemolytic Anemia Hemophilia A or B Iron Deficiency Anemia Leukemia
Languages:
English
Description:
Dr. Bram graduated from the Stanford University School of Medicine in 1987. He works in Rochester, MN and specializes in Internal Medicine. Dr. Bram is affiliated with Saint Marys Hospital.